PGC-1alpha Gly482Ser polymorphism is associated with the plasma adiponectin level in type 2 diabetic men.

Peroxisome proliferator-activated receptor-gamma coactivator-1 alpha (PGC-1alpha) is a multifunctional transcriptional regulator for the pathways controlling mitochondrial biogenesis, oxidative metabolism, and glucose homeostasis. Genetic studies have suggested that Gly482Ser polymorphism of the PGC-1alpha gene is associated with a higher risk of type 2 diabetes, obesity, and hypertension. Adiponectin is an antidiabetic and antiatherogenic adipocytokine that is specifically produced by adipose tissue, and the transcription of the adiponectin gene is regulated by PPARgamma. In this study, we examined the effect of Gly482Ser polymorphism on the plasma adiponectin level in Japanese type 2 diabetics. The Gly482Ser genotype was associated with a lower plasma adiponectin level in type 2 diabetic men, but not in type 2 diabetic women. The impact of this variation on the adiponectin promoter was also assessed by a reporter gene assay, but there was no significant difference between activation by the wild type and Gly482Ser- PGC-1alpha proteins, indicating that this variation itself has no functional effect. Evaluation of the pattern of linkage disequilibrium revealed that the Gly482Ser polymorphism is located in the largest linkage disequilibrium block of the PGC-1alpha gene. Therefore the observed gender-specific association between PGC-1alpha and the plasma adiponectin level may reflect linkage disequilibrium of Gly482Ser polymorphism with other causative variations.

[1]  Y. Pak,et al.  Impaired coactivator activity of the Gly482 variant of peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) on mitochondrial transcription factor A (Tfam) promoter , 2006 .

[2]  M. Ridderstråle,et al.  Increased risk of obesity associated with the variant allele of the PPARGC1A Gly482Ser polymorphism in physically inactive elderly men , 2006, Diabetologia.

[3]  S. O’Rahilly,et al.  Meta-analysis of the Gly482Ser variant in PPARGC1A in type 2 diabetes and related phenotypes , 2006, Diabetologia.

[4]  T. Hansen,et al.  PGC-1α Gly482Ser Polymorphism Associates With Hypertension Among Danish Whites , 2005 .

[5]  C. Bellanné-Chantelot,et al.  The Gly482Ser polymorphism in the peroxisome proliferator-activated receptor-γ coactivator-1 gene is associated with hypertension in type 2 diabetic men , 2004, Diabetologia.

[6]  E. Carlsson,et al.  Multiple environmental and genetic factors influence skeletal muscle PGC-1alpha and PGC-1beta gene expression in twins. , 2004, The Journal of clinical investigation.

[7]  Nader Rifai,et al.  Plasma adiponectin levels and risk of myocardial infarction in men. , 2004, JAMA.

[8]  M. Matsuda,et al.  Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. , 2003, Diabetes.

[9]  O. Pedersen,et al.  A Gly482Ser missense mutation in the peroxisome proliferator-activated receptor gamma coactivator-1 is associated with altered lipid oxidation and early insulin secretion in Pima Indians. , 2003, Diabetes.

[10]  U. Smith,et al.  Reduced expression of PGC-1 and insulin-signaling molecules in adipose tissue is associated with insulin resistance. , 2003, Biochemical and biophysical research communications.

[11]  B. Paulweber,et al.  Peroxisome Proliferator–Activated Receptor-&ggr; Coactivator-1 Gene Locus: Associations with Hypertension in Middle-Aged Men , 2003 .

[12]  Helen Santini.  Rebirth of the health-care system in Cambodia , 2002, The Lancet.

[13]  R. A. Norman,et al.  The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. , 2002, Diabetes.

[14]  M. Matsuda,et al.  Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. , 2002, Diabetes.

[15]  Jonathan Krakoff,et al.  Adiponectin and development of type 2 diabetes in the Pima Indian population , 2002, The Lancet.

[16]  M. Matsuda,et al.  Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 , 2002, Nature Medicine.

[17]  T. Kadowaki,et al.  A genetic variation in the PGC-1 gene could confer insulin resistance and susceptibility to Type II diabetes , 2002, Diabetologia.

[18]  B. Paulweber,et al.  Peroxisome Proliferator-Activated Receptor-γ Coactivator-1 Gene Locus Associations With Obesity Indices in Middle-Aged Women , 2002 .

[19]  T. Hansen,et al.  Mutation analysis of peroxisome proliferator-activated receptor-γ coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to Type II diabetes mellitus , 2001, Diabetologia.

[20]  Y. Terauchi,et al.  The Mechanisms by Which Both Heterozygous Peroxisome Proliferator-activated Receptor γ (PPARγ) Deficiency and PPARγ Agonist Improve Insulin Resistance* , 2001, The Journal of Biological Chemistry.

[21]  Guillaume Adelmant,et al.  Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1 , 2001, Nature.

[22]  M. Matsuda,et al.  PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. , 2001, Diabetes.

[23]  Y. Terauchi,et al.  The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity , 2001, Nature Medicine.

[24]  T. Funahashi,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance , 2022 .

[25]  T Nakamura,et al.  Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. , 1999, Circulation.

[26]  NoriyukiOuchi,et al.  Novel Modulator for Endothelial Adhesion Molecules , 1999 .

[27]  T Nakamura,et al.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. , 1999, Biochemical and biophysical research communications.

[28]  J. Miyazaki,et al.  Mutation P291fsinsC in the Transcription Factor Hepatocyte Nuclear Factor-1α is Dominant Negative , 1998, Diabetes.

[29]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[30]  M. Dieudonné,et al.  Androgen receptors in human preadipocytes and adipocytes: regional specificities and regulation by sex steroids. , 1998, American journal of physiology. Cell physiology.

[31]  P. Puigserver,et al.  A Cold-Inducible Coactivator of Nuclear Receptors Linked to Adaptive Thermogenesis , 1998, Cell.

[32]  Y. Pak,et al.  Impaired coactivator activity of the Gly482 variant of peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha) on mitochondrial transcription factor A (Tfam) promoter. , 2006, Biochemical and biophysical research communications.

[33]  S. Soyal,et al.  PGC-1α: a potent transcriptional cofactor involved in the pathogenesis of type 2 diabetes , 2006, Diabetologia.

[34]  S. O’Rahilly,et al.  Expression of the thermogenic nuclear hormone receptor coactivator PGC-1α is reduced in the adipose tissue of morbidly obese subjects , 2004, International Journal of Obesity.

[35]  T. Funahashi,et al.  Decreased plasma adiponectin concentration in patients with essential hypertension. , 2003, American journal of hypertension.

[36]  P. Boutin,et al.  No association between the G482S polymorphism of the proliferator-activated receptor-gamma coactivator-1 (PGC-1) gene and Type II diabetes in French Caucasians. , 2002, Diabetologia.

[37]  J. Auwerx,et al.  The generation of monoclonal antibodies against human peroxisome proliferator-activated receptors (PPARs). , 2002, Journal of atherosclerosis and thrombosis.

[38]  Y. Terauchi,et al.  The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. , 2001, The Journal of biological chemistry.